Abstract: A method for producing liposomes entrapping Cyclosporine A (CsA). The method comprising preparing a suspension of CsA-free liposomes with a pH level of 7, preparing a mixture with a pH level of 7 by adding the suspension of CsA-free liposomes in the sucrose phosphate buffer to an ethanolic solution of CsA, and forming the liposomes entrapping CsA by incubating the mixture at a temperature level between 42° C. and 48° C. for a time duration between 55 and 65 minutes.

Abstract: A mixture for an injectable scaffold may include a self-assembling core and an additive. The additive may include an angiogenic agent, a small molecule drug, and/or an anti-inflammatory agent. The scaffold can be applied to sites where bone growth is desired.

Abstract: A molecule comprising a lipid, a peptide and a linker to bind the lipid to the peptide which have specific amino acid sequence to bind to Epidermal Growth Factor Receptor (EGFR) of tumor cells, and a liposomal composition which is targeted by the molecule, and method for preparing thereof is disclosed.

Abstract: Disclosed is a liposomal composition for treatment of cancer, which includes at least one PEG-Phospholipid conjugated molecule, cholesterol, and at least one phospholipid.

Abstract: A liposomal composition includes at least two anti-tumor herbal drugs that are simultaneously co-encapsulated. Optionally, the liposomal composition is targeted by adding a monoclonal antibody is added to the liposomes.

Abstract: A mixture for an injectable scaffold may include a self-assembling core and an additive. The additive may include an angiogenic agent, a small molecule drug, and/or an anti-inflammatory agent. The scaffold can be applied to sites where bone growth is desired.

Abstract: A molecule comprising a lipid, a peptide and a linker to bind the lipid to the peptide which have specific amino acid sequence to bind to Epidermal Growth Factor Receptor (EGFR) of tumor cells, and a liposomal composition which is targeted by the molecule, and method for preparing thereof is disclosed.

Abstract: A method for preparing a liposome composition for delivering polyphenolic compounds to the target organs may include preparing a complex that contains at least one polyphenolic compound. Then, encapsulating the polyphenolic compound into a liposome composition by admixing the prepared complex with the liposome ingredients.

Abstract: A liposomal composition includes at least two anti-tumor herbal drugs that are simultaneously co-encapsulated. Optionally, the liposomal composition is targeted by adding a monoclonal antibody is added to the liposomes.

Abstract: Disclosed is a liposomal composition for treatment of cancer, which includes at least one PEG-Phospholipid conjugated molecule, cholesterol, and at least one phospholipid.

Abstract: Modified western blot membranes with silver nanoparticle allow the small peptides of the NS1 protein of the poultry influenza virus to be kept in the membrane and not to diffuse during transferring from the Tricine SDS PAGE. These peptides may differentiate infected from vaccinated poultry.

Abstract: The various embodiments herein provide a method of synthesizing a multi-mode cancer targeted nanoparticles. The method comprises the steps of preparing a plurality of nanoparticles and covalently conjugating monoclonal antibodies on surface of the prepared plurality of nanoparticles. The plurality of nanoparticles consists of a protein and a drug. The protein is Human Serum Albumin protein (HSA) and the drug is methotrexate. The monoclonal antibodies are anti-MUC1 nanobodies. According to an embodiment herein, a multi-mode cancer targeted nanoparticles comprising a plurality of cross linked nanoparticles of protein and drug molecules and covalently linked molecules of monoclonal antibodies. The molecules of monoclonal antibodies are linked on a surface of the plurality of cross linked nanoparticles.

Abstract: Modified western blot membranes with silver nanoparticle allow the small peptides of the NS1 protein of the poultry influenza virus to be kept in the membrane and not to diffuse during transferring from the Tricine SDS PAGE. These peptides may differentiate infected from vaccinated poultry.

Abstract: Provided is a compound and methods for preparation thereof according to formula (I) where A1, A2, A3, and A4 are each a group containing 1 to 40 carbon atoms and at least one carboxylic group, R, R? and R? are each hydrogen or a group containing 1 to 80 carbon atoms, M is bivalent or an element capable of complexing with a pyrrole nitrogen atom, L is a linking group, B is a fullerene, and the compound is soluble in water.

Abstract: The present invention describes the use of the magnetic magnesium isotope 25Mg2+ for the manufacture of a medicament for treating hypoxia. Furthermore, the present invention provides a medicament for treating hypoxia comprising the magnetic magnesium isotope 25Mg2+ and a porphylleren compound according to formula (I) wherein the residues A1, A2, A3, and A4 independently are a group containing 1 to 40 carbon atoms and at least one carboxylic group, the residues R, R? and R? independently are hydrogen or a group containing 1 to 80 carbon atoms, M is 2 H or an element capable of complexing with pyrrole nitrogen atom and L is a linking group and B is a fullerene residue.

Abstract: Provides is a porphylleren compound (and methods for preparation thereof) according to formula (I) where the residues A1, A2 A3, and A4 independently are a group containing 1 to 40 carbon atoms and at least one carboxylic group, the residues R, R? and R? independently are hydrogen or a group containing 1 to 80 carbon atoms, M is 2 H or an element capable of complexing with pyrrole nitrogen atom and L is a linking group and B is a fullerene residue.